Public sector procurement of medicines in Iraq is dominated by the General Company for Marketing of Drugs and Medical Appliances, known by its Arabic acronym KIMADIA. As the procurement arm of the Ministry of Health, KIMADIA is the single largest pharmaceutical purchaser in Iraq, and access to KIMADIA is therefore one of the most consequential commercial questions for any pharmaceutical company operating in or considering the country. The procurement process is governed by general procurement legislation, ministerial instructions, and KIMADIA’s own published tender procedures and conditions, and the experience of dealing with KIMADIA combines elements familiar from public procurement in other markets with specific Iraqi features that should be understood before bidding.
Prequalification
Prequalification is the first major step in supplying KIMADIA. A supplier must be prequalified before being eligible to bid in tenders, and prequalification requires demonstration of legal status, financial capacity, technical capabilities, manufacturing GMP status, product registration in Iraq, track record of supply, and absence of disqualifying issues such as debarment, criminal convictions, or sanctions. Foreign manufacturers participate through authorized Iraqi agents or scientific offices, and the prequalification review covers both the manufacturer and the local representative. Companies often underestimate the lead time and documentation burden of prequalification, it is not a rapid administrative step but a structured assessment that can take months when handled in parallel with other regulatory work.
Tender Process
Tender announcements are published through KIMADIA’s website and trade publications. Tender documents specify the products required, technical specifications, quantities, delivery conditions, packaging and labeling requirements, payment terms, performance security, and evaluation criteria. Sufficient lead time is typically allowed for bid preparation, although the practical workload of preparing a high-quality bid for a complex tender is substantial.
Bids in KIMADIA tenders have technical and commercial components. The technical bid must demonstrate compliance with specifications, including product registration evidence, GMP certification, samples where required, and any other tender-specific documentation. The commercial bid sets out the price per unit, total price, delivery schedule, and other commercial terms. Both components are typically submitted in sealed envelopes by the tender deadline, and deviations, incomplete documentation, late submission, non-conforming products can result in disqualification, sometimes on technicalities that the bidder could easily have avoided.
Evaluation
Evaluation follows a defined process. The technical evaluation excludes non-compliant bids; the commercial evaluation then ranks compliant bids on price and other criteria. Award goes to the most advantageous combination of compliance and price, and for large volume products, KIMADIA may award contracts to multiple bidders to ensure security of supply. The evaluation tends to be more formal than in some other procurement systems, and bidders who base their strategy on relationships rather than on the documented merits of their offer often find that the latter dominates the former in practice.
Contract Performance
Contracts with KIMADIA typically include delivery schedules, quality assurance and inspection rights, payment terms, performance security or bank guarantees, penalties for delay and non-performance, force majeure provisions, and dispute resolution mechanisms. Suppliers should carefully assess their ability to perform contractual obligations before bidding, because KIMADIA enforces contractual provisions actively. Performance security typically takes the form of bank guarantees that secure the supplier’s obligations and are released only on satisfactory completion. Delays, non-conforming product, or other breaches may result in deduction from or forfeiture of the security.
Delivery follows defined protocols. The supplier delivers to specified locations, accompanied by required documentation, and KIMADIA inspects deliveries for compliance with specifications, including packaging, labeling, batch numbers, expiry dates, and quality. Discrepancies may result in rejection of the goods, replacement requirements, or contractual penalties. Acceptance is documented, and payment is processed according to contract terms. The combination of formal acceptance procedures and contractually defined payment terms means that operational discipline at the delivery and documentation stage has direct cash flow consequences for the supplier.
Disputes
Disputes can arise from non-payment, rejection of goods, application of penalties, and disagreements over contract interpretation. They are typically addressed first through commercial negotiation, then through administrative escalation within the Ministry of Health, and ultimately through the Iraqi courts. The Administrative Judiciary has jurisdiction over certain disputes involving public procurement, and arbitration may be available where the contract permits, including international arbitration in some cases. The choice of forum and the management of dispute resolution is often more important than the underlying merits, and contracts should be drafted with realistic dispute scenarios in mind.
Anti-Corruption
Anti-corruption compliance is critical given that pharmaceutical procurement is a focus of anti-corruption enforcement worldwide. Suppliers must ensure that their interactions with KIMADIA officials and evaluation committees are transparent and lawful, and that they comply with Iraqi anti-corruption law as well as extraterritorial regimes such as the US Foreign Corrupt Practices Act and the UK Bribery Act where applicable. Internal compliance programs, due diligence on agents, clear policies on hospitality and gifts, and documented decision-making are all part of the standard package. A single anti-corruption investigation can be more damaging than years of difficult tendering, and prevention is overwhelmingly cheaper than response.
Strategic Considerations
For foreign manufacturers, successful engagement with KIMADIA requires strategic planning aligned with the realities of the Iraqi system. Competitive pricing in light of reference pricing applied to private market registration, currency and payment timeline considerations, and capacity planning to meet delivery commitments all interact. Generic and biosimilar competition is intensifying in KIMADIA tenders, and cost containment is a clear priority. Originator manufacturers should consider value-based strategies, bundling, patient access programs, and partnerships with the Ministry that demonstrate value beyond unit price. Generic and biosimilar companies need to demonstrate quality, regulatory compliance, and reliable supply to win and retain KIMADIA business.
How We Can Help
Etihad Law Firm advises pharmaceutical manufacturers, agents, and scientific offices on KIMADIA prequalification and tenders, contract negotiation and performance, dispute resolution, and anti-corruption compliance. We provide both transactional support for individual tenders and strategic advice on long-term public sector engagement in Iraq.